在心力衰竭中选择性无效阴道刺激
Lindsea C Booth1, Baagavi Saseetharan1, Clive N May1
1Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.
Experimental physiology
|September 27, 2023
概括
阴道神经刺激在心力衰竭患者中显示出混合的结果. 新的方法选择性地准心脏发射的阴道纤维,通过改善治疗结果,为心力衰竭提供潜在的治疗方法.
科学领域:
- 心血管医学 心血管医学
- 神经科学是一个神经科学.
- 医疗器械 医疗器械
背景情况:
- 心力衰竭带来了显著的死亡率和发病率挑战.
- 对心力衰竭的神经刺激 (VNS) 试验产生了不一致的结果.
- 目前VNS的局限性包括非选择性纤维招募和未知的治疗点.
研究的目的:
- 审查选择性准心脏投射的异位阴道纤维的潜力.
- 在心力衰竭中引入一种选择性阴道神经刺激的新方法.
主要方法:
- 专注于源自背部运动核的无效阴道纤维.
- 对这些特定的神经通路的选择性准技术的审查.
- 探索阴道神经刺激作为治疗策略.
主要成果:
- 选择性招募特定的阴道纤维对于有效的VNS至关重要.
- 识别和向心脏发射的阴道纤维可能会提高治疗效率.
- 临床前数据表明,有针对性的VNS具有潜在的益处.
结论:
- 针对心脏投射的选择性神经刺激为心力衰竭提供了一个有希望的治疗途径.
- 对有针对性的VNS进行进一步研究是有必要的,以克服当前方法的局限性.
- 这种方法可以改善心力衰竭患者的结果.
相关概念视频
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure Drugs: Inotropic Agents
611
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
611
Heart Failure Drugs: β-Blockers
357
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
357
Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454


